PURPOSE: Obese women with breast cancer have worse prognosis than women with normal body mass index. Endocrine therapy resistance is in part mediated by insulin resistance in obese women with breast cancer. We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer. METHODS: Patients had previously received chemotherapy and endocrine therapy for breast cancer. Exemestane was given as 25 mg orally per day. Metformin (M) and rosiglitazone (R) were given twice daily. Dose level 1 consisted of M 1,500 mg/day and R 6 mg/day. Dose level 2 consisted of M 2,000 mg/day and R 8 mg/day. Plasma concentrations of exemestane were measured on days 1, 8, and 15. RESULTS: Twenty patients were enrolled. Fourteen patients received exemestane, metformin, and rosiglitazone. Six patients received exemestane with metformin only (2,000 mg/day). Both regimens were well tolerated at the highest doses tested, and there were no notable changes in plasma exemestane levels. Six patients (30%) had stable disease for 6 months or longer. CONCLUSIONS: Oral daily administration of exemestane (25 mg) and metformin (2,000 mg) with and without rosiglitazone (8 mg) daily was well tolerated. Exemestane pharmacokinetics were not altered by metformin and rosiglitazone.
PURPOSE:Obesewomen with breast cancer have worse prognosis than women with normal body mass index. Endocrine therapy resistance is in part mediated by insulin resistance in obesewomen with breast cancer. We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer. METHODS:Patients had previously received chemotherapy and endocrine therapy for breast cancer. Exemestane was given as 25 mg orally per day. Metformin (M) and rosiglitazone (R) were given twice daily. Dose level 1 consisted of M 1,500 mg/day and R 6 mg/day. Dose level 2 consisted of M 2,000 mg/day and R 8 mg/day. Plasma concentrations of exemestane were measured on days 1, 8, and 15. RESULTS: Twenty patients were enrolled. Fourteen patients received exemestane, metformin, and rosiglitazone. Six patients received exemestane with metformin only (2,000 mg/day). Both regimens were well tolerated at the highest doses tested, and there were no notable changes in plasma exemestane levels. Six patients (30%) had stable disease for 6 months or longer. CONCLUSIONS: Oral daily administration of exemestane (25 mg) and metformin (2,000 mg) with and without rosiglitazone (8 mg) daily was well tolerated. Exemestane pharmacokinetics were not altered by metformin and rosiglitazone.
Authors: John R Benson; Ismail Jatoi; Martin Keisch; Francisco J Esteva; Andreas Makris; V Craig Jordan Journal: Lancet Date: 2009-04-25 Impact factor: 79.321
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: C R Sirtori; G Franceschini; M Galli-Kienle; G Cighetti; G Galli; A Bondioli; F Conti Journal: Clin Pharmacol Ther Date: 1978-12 Impact factor: 6.875
Authors: D C Johannessen; T Engan; E Di Salle; M G Zurlo; J Paolini; G Ornati; G Piscitelli; S Kvinnsland; P E Lonning Journal: Clin Cancer Res Date: 1997-07 Impact factor: 12.531
Authors: Clinton Yam; Francisco J Esteva; Miral M Patel; Akshara S Raghavendra; Naoto T Ueno; Stacy L Moulder; Kenneth R Hess; Girish S Shroff; Silvia Hodge; Kimberly H Koenig; Mariana Chavez Mac Gregor; Robin L Griner; Sai-Ching J Yeung; Gabriel N Hortobagyi; Vicente Valero Journal: Invest New Drugs Date: 2019-01-05 Impact factor: 3.850
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254
Authors: Donna L Nile; Colin Rae; David J Walker; Joe Canning Waddington; Isabel Vincent; Karl Burgess; Mark N Gaze; Robert J Mairs; Anthony J Chalmers Journal: Cancer Metab Date: 2021-05-19
Authors: Enrique Fuentes-Mattei; Guermarie Velazquez-Torres; Liem Phan; Fanmao Zhang; Ping-Chieh Chou; Ji-Hyun Shin; Hyun Ho Choi; Jiun-Sheng Chen; Ruiying Zhao; Jian Chen; Chris Gully; Colin Carlock; Yuan Qi; Ya Zhang; Yun Wu; Francisco J Esteva; Yongde Luo; Wallace L McKeehan; Joe Ensor; Gabriel N Hortobagyi; Lajos Pusztai; W Fraser Symmans; Mong-Hong Lee; Sai-Ching Jim Yeung Journal: J Natl Cancer Inst Date: 2014-06-23 Impact factor: 13.506